Continuous low-dose apatinib combined with WBRT significantly reduces peritumoral edema and enhances the efficacy of symptomatic multiple brain metastases in …
Y Ren, SB Wang, L Zhou, SQ Liu… - … in Cancer Research …, 2021 - journals.sagepub.com
Background: Symptomatic multiple brain metastases with peritumoral brain edema (PTBE)
occur in non-small cell lung cancer patients (NSCLC) who are without driver mutations or …
occur in non-small cell lung cancer patients (NSCLC) who are without driver mutations or …
[HTML][HTML] Efficacy and safety of apatinib combined with whole-brain radiation therapy with a simultaneous integrated boost for brain metastases from non-small cell lung …
J Ma, J Bi, X Tuo, G Pi, Y Li, Y Li, F Zeng… - Journal of Thoracic …, 2022 - ncbi.nlm.nih.gov
Background Brain metastases (BMs) develop in 20–65% of non-small cell lung cancer
(NSCLC) patients and are associated with a poor prognosis. Apatinib, a tyrosine kinase …
(NSCLC) patients and are associated with a poor prognosis. Apatinib, a tyrosine kinase …
[HTML][HTML] Apatinib monotherapy or combination therapy for non-small cell lung cancer patients with brain metastases
J Xu, X Liu, S Yang, Y Shi - Oncology Research, 2020 - ncbi.nlm.nih.gov
Apatinib, an oral small molecular receptor tyrosine kinase inhibitor (TKI) developed first in
China, exerts antiangiogenic and antineoplastic function through selectively binding and …
China, exerts antiangiogenic and antineoplastic function through selectively binding and …
Concurrent Apatinib and Brain Radiotherapy in Patients With Brain Metastases From Driver Mutation-negative Non–small-cell Lung Cancer: Study Protocol for an …
J Ma, G Pi, J Bi, Y Li, H He, Y Li, D Hu, V Verma… - Clinical Lung Cancer, 2021 - Elsevier
Brain radiotherapy (BR) is a well-recognized approach for multiple brain metastases (BMs)
from non–small-cell lung cancer (NSCLC). However, the prognosis for these patients …
from non–small-cell lung cancer (NSCLC). However, the prognosis for these patients …
[HTML][HTML] Perilesional edema in brain metastases as predictive factor of response to systemic therapy in non-small cell lung cancer patients: a preliminary study
M Alemany, M Domènech, AA Argyriou… - Annals of …, 2021 - ncbi.nlm.nih.gov
Background The significance of upfront systemic therapies as an alternative to whole brain
radiotherapy (WBRT) for multiple brain metastases (BM) is debatable. Our purpose is to …
radiotherapy (WBRT) for multiple brain metastases (BM) is debatable. Our purpose is to …
[HTML][HTML] Apatinib plus docetaxel or pemetrexed shows promising activities against non-small cell lung cancer with brain metastasis: a retrospective analysis
J Tang, H Jiang, Z Xiang, X Zhu, R Xie… - Journal of Thoracic …, 2024 - ncbi.nlm.nih.gov
Background So far, the treatment options for most advanced non-small cell lung cancer
(NSCLC) with brain metastasis have been limited. Apatinib, an oral tyrosine kinase inhibitor …
(NSCLC) with brain metastasis have been limited. Apatinib, an oral tyrosine kinase inhibitor …
Bevacizumab reduces peritumoral brain edema in lung cancer brain metastases after radiotherapy
YC Hua, DZ Gao, KY Wang, XS Ding, WR Xu… - Thoracic …, 2023 - Wiley Online Library
Background The aim of this study was to investigate the efficacy of bevacizumab (Bev) in
reducing peritumoral brain edema (PTBE) after stereotactic radiotherapy (SRT) for lung …
reducing peritumoral brain edema (PTBE) after stereotactic radiotherapy (SRT) for lung …
Efficacy of apatinib+radiotherapy vs radiotherapy alone in patients with advanced multiline therapy failure for non small cell lung cancer with brain metastasis
H Pan, X Zhou, L Shen, Y Li, W Dong… - The British Journal of …, 2023 - academic.oup.com
Objective: Lung cancer is the leading cause of cancer-associated mortality worldwide.
Central nervous system (CNS) metastasis is a prevalent and serious complication. The most …
Central nervous system (CNS) metastasis is a prevalent and serious complication. The most …
Clinical response to apatinib combined with brain radiotherapy in EGFR wild-type and ALK-negative lung adenocarcinoma with multiple brain metastases
X Ying, H Liu, M Wang, M Peng, P Ruan… - Frontiers in …, 2020 - frontiersin.org
Background: Brain radiotherapy is the standard treatment option for multiple brain
metastases (BMs) from non-small cell lung cancer (NSCLC), especially in the absence of a …
metastases (BMs) from non-small cell lung cancer (NSCLC), especially in the absence of a …
[HTML][HTML] A pooled analysis of advanced nonsquamous non-small cell lung cancer patients with stable treated brain metastases in two phase II trials receiving …
MA Gubens, JC Chuang, W Akerley… - Journal of Thoracic …, 2018 - ncbi.nlm.nih.gov
Background Brain metastases are a common complication of advanced non-small cell lung
cancer (NSCLC). Patients with brain metastases were excluded from the registration trials of …
cancer (NSCLC). Patients with brain metastases were excluded from the registration trials of …
相关搜索
- lung cancer brain metastases
- peritumoral edema brain metastases
- safety of apatinib brain metastases
- therapy for patients brain metastases
- concurrent apatinib brain radiotherapy
- bevacizumab and pemetrexed brain metastases
- clinical response brain metastases
- pooled analysis brain metastases
- predictive factor brain metastases
- concurrent apatinib brain metastases
- apatinib monotherapy brain metastases
- perilesional edema brain metastases
- efficacy and safety brain metastases
- combination therapy brain metastases
- radiation therapy brain metastases
- systemic therapy brain metastases